Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Pavese, Janet M ^a   Ogden, Irene M ^a   Voll, Eric A ^a   Huang, Xiaoke ^a   Xu, Li ^a   Jovanovic, Borko ^a,b   Bergan, Raymond C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEINASE; STRESS ACTIVATED PROTEIN KINASE 1; MAP2K4 PROTEIN, HUMAN; MMP2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME STABILITY; ENZYME SYNTHESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84904251396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102289     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Zelefsky M, Eastham J, Sartor O, Kantoff P (2008) Cancer of the Prostate, in Cancer: Principles and Practice of Oncology. New York: Lippincott Williams and Wilkins.
3. Whitmarsh AJ, Davis RJ (2007) Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26: 3172-3184. (Pubitemid 46763013)
4. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, et al. (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 58: 2339-2342. (Pubitemid 28252690)
5. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, et al. (2006) Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 5: 630-634. (Pubitemid 44024717)
6. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, et al. (2005) Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 65: 10984-10991. (Pubitemid 41713368)
7. Szmulewitz RZ, Clark R, Lotan T, Otto K, Taylor Veneris J, et al. (2012) MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer 130: 509-520.
8. del Barco Barrantes I, Nebreda AR (2012) Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 40: 79-84.
9. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, et al. (2007) Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol 212: 386-394. (Pubitemid 47099015)
10. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, et al. (2001) Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 61: 2833-2837. (Pubitemid 32691920)
11. Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, et al. (2009) MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst 101: 1141-1155.
12. Huang X, Chen S, Xu L, Liu Y, Deb DK, et al. (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65: 3470-3478. (Pubitemid 40524634)
13. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, et al. (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68: 2024-2032. (Pubitemid 351416590)
14. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC (2003) p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22: 4841-4850. (Pubitemid 36981272)
15. Xu L, Chen S, Bergan RC (2006) MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25: 2987-2998. (Pubitemid 43780463)
16. Xu L, Bergan RC (2006) Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor beta-Mediated Activation of Mitogen-Activated Protein Kinase- Activated Protein Kinase 2-27-kDa Heat Shock Protein Pathway. Mol Pharmacol 70: 869-877. (Pubitemid 44268444)
17. Wang L, Pan Y, Dai JL (2004) Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 23: 5978-5985. (Pubitemid 39093542)
18. Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Calhoun ES, et al. (2006) Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res 66: 5560-5564. (Pubitemid 43927105)
19. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, et al. (2006) The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66: 2264-2270.
20. Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, et al. (2011) MKK4 acts as a potential tumor suppressor in ovarian cancer. Tumour Biol 32: 661-670.
21. Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri A, et al. (2010) Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer. Oncology 79: 238-246.
22. Liu YQ, Kyle E, Patel S, Housseau F, Hakim F, et al. (2001) Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis 4: 81-91. (Pubitemid 32633383)
23. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC (2002) Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21: 8272-8281. (Pubitemid 35477867)
24. ATCC (2007) Cell Line Verification Test Recommendations. ATCC Technical Bulletin No.8: 1-3.
25. Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, et al. (2011) Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28: 39-53.
26. Craft CS, Xu L, Romero D, Vary CP, Bergan RC (2008) Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol Pharmacol 73: 235-242. (Pubitemid 350294214)
27. Ding Y, Xu L, Jovanovic BD, Helenowski IB, Kelly DL, et al. (2007) The methodology used to measure differential gene expression affects the outcome. J Biomol Tech 18: 321-330.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
29. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ (1995) Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407.
30. Huang X, Chen S, Xu L, Liu YQ, Deb DK, et al. (2005) Genistein inhibits p38 MAP kinase activation, MMP-2, and cell invasion in human prostate epithelial cells. Cancer Research 65: 3470-3478. (Pubitemid 40524634)
31. Vihinen P, Ala-aho R, Kahari VM (2005) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5: 203-220. (Pubitemid 40694861)
32. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40. (Pubitemid 32225829)
33. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, et al. (2011) Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 16: 1028-1041.
34. Ben-Ami I, Yao Z, Naor Z, Seger R (2011) Gq protein-induced apoptosis is mediated by AKT kinase inhibition that leads to protein kinase C-induced c-Jun N-terminal kinase activation. J Biol Chem 286: 31022-31031.
35. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW Jr (2011) CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif 44: 311-319.
36. Bjorkblom B, Padzik A, Mohammad H, Westerlund N, Komulainen E, et al. (2012) c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells. Mol Cell Biol 32: 3513-3526.
37. Liu KC, Huang AC, Wu PP, Lin HY, Chueh FS, et al. (2011) Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep 26: 177-184.
38. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2010) Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 28: 145-151.
39. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, et al. (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602. (Pubitemid 39297919)
40. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, et al. (2005) Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65: 11083-11093. (Pubitemid 41713379)
41. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, et al. (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105. (Pubitemid 32059190)
42. Stearns ME, Wang M (1993) Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53: 878-883. (Pubitemid 23077878)
43. Stearns M, Stearns ME (1996) Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8: 69-75. (Pubitemid 26134926)
44. Stearns ME, Stearns M (1996) Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol Res 8: 63-67.
45. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, et al. (1997) In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15: 246-258. (Pubitemid 27240355)
46. Liang H, Gu M, Yang C, Wang H, Wen X, et al. (2012) Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth 26: 381-392.
47. Shen KH, Hung SH, Yin LT, Huang CS, Chao CH, et al. (2010) Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem 333: 279-291.
48. Schilling D, Todenhofer T, Hennenlotter J, Schwentner C, Fehm T, et al. (2012) Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol.